Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Expands By 97.0%

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 291,500 shares, an increase of 97.0% from the February 28th total of 148,000 shares. Based on an average daily volume of 566,700 shares, the short-interest ratio is presently 0.5 days. Approximately 10.6% of the shares of the stock are short sold.

Institutional Trading of Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. bought a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio at the end of the most recent reporting period. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Trading Up 1.5 %

Shares of PALI traded up $0.01 during midday trading on Friday, reaching $0.70. The stock had a trading volume of 25,056 shares, compared to its average volume of 761,427. The company has a market capitalization of $1.94 million, a price-to-earnings ratio of -0.05 and a beta of 1.49. The company’s 50-day moving average is $1.04 and its 200 day moving average is $2.11. Palisade Bio has a 12-month low of $0.65 and a 12-month high of $9.65.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($2.39) by $1.70. Research analysts forecast that Palisade Bio will post -12.43 EPS for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.